CL2004000754A1 - Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. - Google Patents

Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.

Info

Publication number
CL2004000754A1
CL2004000754A1 CL200400754A CL2004000754A CL2004000754A1 CL 2004000754 A1 CL2004000754 A1 CL 2004000754A1 CL 200400754 A CL200400754 A CL 200400754A CL 2004000754 A CL2004000754 A CL 2004000754A CL 2004000754 A1 CL2004000754 A1 CL 2004000754A1
Authority
CL
Chile
Prior art keywords
imidazol
piperidine
phenyl
prepare
prevent
Prior art date
Application number
CL200400754A
Other languages
English (en)
Spanish (es)
Inventor
Thomas H W Janssens F Steckler
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2004000754A1 publication Critical patent/CL2004000754A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL200400754A 2003-04-11 2004-04-07 Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. CL2004000754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0303879 2003-04-11

Publications (1)

Publication Number Publication Date
CL2004000754A1 true CL2004000754A1 (es) 2005-02-25

Family

ID=33154992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400754A CL2004000754A1 (es) 2003-04-11 2004-04-07 Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.

Country Status (12)

Country Link
US (1) US20060287345A1 (https=)
EP (1) EP1615644B1 (https=)
JP (1) JP2006522775A (https=)
AR (1) AR044010A1 (https=)
AT (1) ATE353649T1 (https=)
AU (1) AU2004228960A1 (https=)
CA (1) CA2521186A1 (https=)
CL (1) CL2004000754A1 (https=)
DE (1) DE602004004771T2 (https=)
ES (1) ES2282858T3 (https=)
TW (1) TW200509913A (https=)
WO (1) WO2004089372A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
JP2011030565A (ja) * 2009-07-06 2011-02-17 Yokohama City Univ 社会的隔離モデル動物
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
CA2911231C (en) * 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
CN113292559B (zh) 2015-03-17 2024-04-02 日本化学药品株式会社 吗啡喃衍生物
US20210371422A1 (en) 2016-08-09 2021-12-02 Nippon Chemiphar Co., Ltd. Morphinan derivative
US11633392B2 (en) 2016-09-16 2023-04-25 Nippon Chemiphar Co., Ltd. Use of morphinan derivative for therapeutic treatment of opioid delta receptor agonist-related disease
MA52482B1 (fr) 2018-05-01 2024-12-31 Merck Sharp & Dohme Llc Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
AU2020385852A1 (en) 2019-11-22 2022-06-02 Nippon Chemiphar Co., Ltd. Pyrazolomorphinan derivative
CA3211977A1 (en) 2021-02-26 2022-09-01 Tokyo University Of Science Foundation Pharmaceutical composition for treatment or prevention of stress-related disorders
US20220305020A1 (en) * 2021-03-26 2022-09-29 Ingenious Ingredients, LP The use of paraxanthine to reduce exercise-induced mental fatigue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354863A (en) * 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds
DE19805370A1 (de) * 1997-03-14 1998-09-17 Gruenenthal Gmbh Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
DE19939044A1 (de) * 1999-08-18 2001-03-15 Gruenenthal Gmbh Verwendung von Morphinanderivaten als Arzneimittel
SE0101767D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
BR0213325A (pt) * 2001-10-15 2004-10-13 Janssen Pharmaceutica Nv Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìda para a redução de dano isquêmico
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов

Also Published As

Publication number Publication date
TW200509913A (en) 2005-03-16
AR044010A1 (es) 2005-08-24
ES2282858T3 (es) 2007-10-16
DE602004004771D1 (de) 2007-03-29
EP1615644B1 (en) 2007-02-14
DE602004004771T2 (de) 2007-12-06
JP2006522775A (ja) 2006-10-05
EP1615644A1 (en) 2006-01-18
AU2004228960A1 (en) 2004-10-21
US20060287345A1 (en) 2006-12-21
WO2004089372A1 (en) 2004-10-21
CA2521186A1 (en) 2004-10-21
ATE353649T1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
CL2004000695A1 (es) Compuestos derivados de 4-fenil piperidina, composicion farmaceutica, util como modulador del receptor opioides, para tratar sindrome de intestino irritable, adiccion o dependencia de drogas, depresion, ansiedad, esquizofrenia, trastornos de la alime
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
SG170813A1 (en) New compounds
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
CL2004000754A1 (es) Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
CL2011000478A1 (es) Compuestos derivados de 2-imidazol-propanamida sustituidos, activadores de glucoquinasa; composicion farmaceutica, util para tratar o retrasar la progresion o aparacion de la diabetes tipo ii o trastornos relacionados con la diabetes.
SV2008002365A (es) Compuestos de quinolina heteroaromaticos ref. pc32593a
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
TW200732296A (en) Novel compounds
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
TW200732321A (en) Fast dissociating dopamine 2 receptor antagonists
MX2009008616A (es) Antagonistas del receptor de dopamina 2 de rapida disociacion.
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
JO2642B1 (en) Dopamine 2 receptor antagonists are rapidly hydrolyzed